Vir Biotechnology SVP sells shares under 10b5-1

Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini reported an open-market sale of 379 shares of common stock at $9.45 per share.

Accepted by SEC EDGAR 06/02/2026 - 05:31 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini reported an open-market sale of 379 shares of common stock at $9.45 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan. After this small sale, he directly holds 61,902 shares.

The footnotes note that the 379 shares sold had been acquired on May 29, 2026 through an employee stock purchase program, indicating this filing reflects routine, pre-planned portfolio activity rather than a large discretionary transaction.

Insider Trade Summary 10b5-1

Net Seller: 379 shares

Net Sell 1 txn

Insider Sabatini Brent

Role SVP, Chief Accounting Officer

Sold 379 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	379	$9.45	$4K

Holdings After Transaction: Common Stock — 61,902 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
2. F2. Includes 379 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program.

Key Figures

Shares sold: 379 shares Sale price: $9.45 per share Shares held after sale: 61,902 shares +3 more

6 metrics

Shares sold 379 shares Open-market sale of common stock on June 1, 2026

Sale price $9.45 per share Price received in the reported open-market sale

Shares held after sale 61,902 shares Direct ownership following the June 1, 2026 transaction

Net shares sold 379 shares Net change in position from this Form 4 transaction

10b5-1 plan adoption date December 19, 2025 Date Sabatini adopted the Rule 10b5-1 trading plan

ESPP acquisition date May 29, 2026 Date the 379 shares were acquired via employee stock purchase program

Key Terms

Rule 10b5-1 trading plan, employee stock purchase program, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

employee stock purchase program financial

"shares of common stock acquired ... pursuant to an employee stock purchase program"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vir Biotechnology (VIR) report for Brent Sabatini?

Vir Biotechnology reported that SVP and Chief Accounting Officer Brent Sabatini sold 379 shares of common stock in an open-market transaction. The sale was executed at $9.45 per share and disclosed in a Form 4 insider trading report filed with regulators.

At what price did Brent Sabatini sell Vir Biotechnology (VIR) shares?

Brent Sabatini sold 379 Vir Biotechnology common shares at $9.45 per share. This reflects a small open-market sale, documented in a Form 4 filing and carried out pursuant to a pre-arranged Rule 10b5-1 trading plan established in advance.

How many Vir Biotechnology (VIR) shares does Brent Sabatini hold after this sale?

After the reported transaction, Brent Sabatini holds 61,902 Vir Biotechnology common shares directly. This shows the 379 shares sold represent only a small fraction of his total holdings, suggesting the filing reflects routine, ongoing equity ownership rather than a major position change.

Was Brent Sabatini’s Vir Biotechnology (VIR) share sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the sale was effected under a Rule 10b5-1 trading plan adopted on December 19, 2025. Such plans pre-schedule trades, indicating the timing of this 379-share sale was predetermined rather than a spontaneous market-timing decision.

How were the 379 Vir Biotechnology (VIR) shares originally acquired by Brent Sabatini?

Footnotes explain the 379 shares sold were acquired on May 29, 2026 through an employee stock purchase program. The Form 4 therefore shows Sabatini first obtained these shares via a company plan and then sold the same amount days later under his 10b5-1 trading arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabatini Brent

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		379	D	$9.45	61,902(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.

2. Includes 379 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)